Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Redwoods Acquisition's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Redwoods Acquisition (RWODU) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026
Competitors Tracked
1
Publicly traded peers
Peer Group Market Share
-
Share of combined sales, Q2 2026
Revenue Growth Y/Y
-
Peers: -21.78 %
Net Margin
-
Peers: -32.55 %
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/RWODU/competitors
https://api.csimarket.com/api/v1/companies/RWODU/relationships
https://api.csimarket.com/api/v1/companies/RWODU/similar
Programmatic access for models, analytics, and integration workflows.

Redwoods Acquisition's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Redwoods Acquisition Corp - - - No
Competitors combined (1) 0% 0% 0% 100%
High-Confidence Competitors (2) 100% 100% 0% 50%

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

RWODU Stock Performance relative to its Competitors

RWODU Competitors (weighted) Percent change over the selected range

Redwoods Acquisition's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
0%beat U.S.A. 500
Competitors Combined
(0 of 1)
50%beat U.S.A. 500
High-Confidence
(1 of 2)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
Redwoods Acquisition Corp - -
Competitors combined (1) 40.4% 63.2%
High-Confidence Competitors (2) 40.4% 63.2%
Similar-Size Competitors (0) 40.4% 63.2%
Similar Growth & Profitability (0) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Redwoods Acquisition's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

RWODU Stock Performance relative to High-Confidence Competitors

RWODU High-Confidence Competitors (equal-weighted, 4) Percent change over the selected range

5 Best-Performing Tracked Competitors, Trailing 12 Months

#CompetitorTTM Share Price Returnvs U.S.A. 500
1 Buzzfeed Inc 282.9% Outperformed
Best-Performing Competitor Returns

TTM share price return and U.S.A. 500 outperformance for Redwoods Acquisition's best-performing tracked competitors requires a Commercial License.

Source: CSIMarket API, trailing 12 months.

Redwoods Acquisition's Comment on Competition and Industry Peers

The competitive landscape for Alzheimer's disease therapeutics includes anti-amyloid antibodies such as aducanumab (Biogen: Aduhelm) and lecanemab (Lilly: Leqembi), both of which received FDA approval. Aducanumab was recently withdrawn from the market due to lack of effectiveness and serious side effects. Multiple large and early-stage pharmaceutical companies are developing treatments for Alzheimer's disease. Few companies reference Klotho or Klotho gene therapy; ADvantage Therapeutics mentions Klotho, while Unity Biotechnology, a startup focused on drugs targeting senescent cells, is the leading competitor in Klotho gene therapy. Unity Biotechnology has licensed Dubal Klotho technology but has not published data or clinical trials. Regulatory approval is required in Europe, Japan, and other countries to market products outside the U.S., with each jurisdiction imposing its own requirements. Competitors identified include ADvantage Therapeutics, Biogen, Bristol-Myers/Celgene, Lilly, Roche, and Unity Biotechnology.

Publicly Traded Peers of Redwoods Acquisition Corp

Revenue and income for trailing 12 months, in millions of $, except employees
Company Market Cap Revenues Income Employees
Redwoods Acquisition Corp 980.54 - -21.77 -
Buzzfeed Inc 62.25 170.71 -61.20 507
SUBTOTAL 1,042.79 170.71 -82.97 507

Sources: Redwoods Acquisition Corp's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Redwoods Acquisition Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.

Redwoods Acquisition's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
ADvantage Therapeutics Named by the company 85% 2022 to 2026 3
Roche Named by the company 85% 2022 to 2026 3
Bristol-Myers/Celgene Named by the company 85% 2022 to 2026 3
Bayer AG Named by the company 85% 2022 to 2026 3
UC San Diego School of Medicine Named by the company 85% 2022 to 2026 3
Lilly Named by the company 85% 2022 to 2026 3
Biogen Named by the company 85% 2022 to 2026 3
Unity Biotechnology Named by the company 85% 2022 to 2026 3
Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Redwoods Acquisition's named competitors require a Commercial License.

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.

Redwoods Acquisition's Productivity vs Peers Comparison

Revenue and income per employee, trailing 12 months, in $; market cap in millions of $
CompanyMarket CapRevenue / EmployeeIncome / Employee
Redwoods Acquisition Corp 981 - -
Buzzfeed Inc 62 336,708 -120,714
PEERS TOTAL 62 336,708 -120,714

Redwoods Acquisition's Geographic Revenue Exposure vs Peers

Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.
Company Largest Market 2nd Market 3rd Market
Buzzfeed Inc United States 94.25 % Non-US 5.75 % -

Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.

Redwoods Acquisition's Position in Industry Market Structure

Market-capitalization share and concentration across all 159 companies in Redwoods Acquisition's industry classification, broader than the peer set above. Market cap in millions of $.

Redwoods Acquisition ranks #0 of 159 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,317, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).

Rank Company Market Cap Industry Share
1 Amgen Inc 229,301 26.04 %
2 Gilead Sciences Inc 185,269 21.04 %
3 Moderna Inc 76,643 8.70 %
4 Argenx Se 63,316 7.19 %
5 Revolution Medicines Inc 1,234 5.2%
6 Biogen Inc 1,234 5.2%
7 Biontech Se 1,234 5.2%
8 Exelixis Inc 1,234 5.2%
9 Neurocrine Biosciences Inc 1,234 5.2%
10 Halozyme Therapeutics Inc 1,234 5.2%
0 Redwoods Acquisition Corp 304 0.00 %
Full Industry Market Structure

Market cap and industry share for the rest of Redwoods Acquisition's industry peers requires a Commercial License.

Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2024-06-21.

Redwoods Acquisition's Multi-Year Financial Trajectory

Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.
Metric 202220242025
Revenue Growth ---
Operating Margin ---
Return on Invested Capital --137.81 %-46.44 %
P/E ---

Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.

Redwoods Acquisition's Competitive Forces (Porter's Five Forces)

Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.
Force Assessment Basis
Competitive Rivalry High Industry HHI of 1,317 (see Industry Market Structure & Concentration above)
Supplier Power Not covered on this page See Redwoods Acquisition's dedicated suppliers page for concentration and dependency data
Buyer Power Not covered on this page See Redwoods Acquisition's dedicated customers page for concentration and dependency data
Threat of Substitutes - No systematic data source for cross-product substitution exists in this system; not estimated

Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.

Redwoods Acquisition's SWOT

Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.

Strengths

No rule matched.

Weaknesses

  • Return on equity 64.2 points below the industry aggregate.

Opportunities

  • Industry revenue growing at a healthy 10.0% median pace.
  • A meaningful share of tracked competitors (100.00 %) show financial-distress signals, a possible opening to gain share.

Threats

  • Tracked peer group's revenue run-rate is broadly decelerating (-15.0% annualized).

Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.

Redwoods Acquisition's Financial Strength vs Peers Comparison

Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months
CompanyQuick RatioWorking CapitalDebt / EquityAsset Turnover
Redwoods Acquisition Corp 13.70 19.76 - -
Buzzfeed Inc 0.19 0.89 0.94 0.95

Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.

Redwoods Acquisition's Revenue and Income Growth vs Peers

Quarterly revenue and net income growth, year over year and quarter over quarter
CompanyPeriodRevenue Y/YRevenue Q/QIncome Y/YIncome Q/Q
Redwoods Acquisition CorpQ2 2026----
Buzzfeed Inc Q2 2026-21.8 %+14.9 %--
PEERS TOTAL-21.8 %+14.9 %--

Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.

Redwoods Acquisition's Peers' Costs of Sales and Capital Expenditures

Context for revenue growth: peer costs and capex, year over year and quarter over quarter
CompanyPeriodCosts Y/YCosts Q/QCapex Y/YCapex Q/Q
Redwoods Acquisition CorpQ2 2026----
Buzzfeed Inc Q2 2026-18.6 %+1.9 %-18.0 %-28.4 %

Redwoods Acquisition's Returns and Turnover vs Peers

ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover
CompanyROAROIROEReceivables TurnoverInventory Turnover
Redwoods Acquisition Corp-----
Buzzfeed Inc ---4.91-

ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).

Redwoods Acquisition's Valuation vs Peers

P/E, price to sales, PEG, price to cash flow and price to book
CompanyP/EPrice / SalesPEGP/CFPrice / Book
Redwoods Acquisition Corp---1,073.4616.93
Buzzfeed Inc -0.36--1.21
PEERS AVERAGE-6.11-9.54

P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.

Get the full CSIMarket dataset: Subscribe API License